Guardant Health, Inc. $GH Stock: Sicart Associates LLC Decreases Position

Key Points

• Sicart Associates cut its Guardant Health position by 21.6% in the third quarter, selling 49,985 shares and retaining 181,030 shares worth approximately $32.3 million. The stock remains the fund’s second-largest holding at 7.7% of its portfolio.
• Guardant Health has attracted substantial institutional interest, with several investment firms initiating sizable positions; institutional investors collectively own 92.6% of the company.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $191. The company also reported better-than-expected quarterly results, including $335 million in revenue—up 44.3% year over year—and a narrower-than-expected loss.

Sicart Associates LLC decreased its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 21.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 181,030 shares of the company's stock after selling 49,985 shares during the period. Guardant Health comprises approximately 7.7% of Sicart Associates LLC's portfolio, making the stock its 2nd biggest holding. Sicart Associates LLC owned about 0.13% of Guardant Health worth $32,289,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new position in Guardant Health during the 2nd quarter valued at about $208,592,000. William Blair Investment Management LLC bought a new stake in shares of Guardant Health in the 2nd quarter worth approximately $196,737,000. Orbimed Advisors LLC bought a new stake in shares of Guardant Health in the 1st quarter worth approximately $40,199,000. Eagle Health Investments LP purchased a new position in shares of Guardant Health during the second quarter valued at approximately $45,112,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Guardant Health during the second quarter valued at approximately $32,316,000. Institutional investors own 92.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Royal Bank Of Canada raised their price target on Guardant Health from $185.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Rothschild & Co Redburn initiated coverage on Guardant Health in a research report on Tuesday, September 8th. They set a "buy" rating and a $203.00 price objective on the stock. UBS Group upped their price objective on shares of Guardant Health from $175.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $210.00 price target on shares of Guardant Health in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their target price on Guardant Health from $185.00 to $195.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $191.00.

Guardant Health Price Performance

NASDAQ:GH opened at $178.80 on Monday. The stock's 50 day simple moving average is $169.71 and its two-hundred day simple moving average is $130.68. Guardant Health, Inc. has a 1 year low of $74.55 and a 1 year high of $191.05. The company has a market cap of $23.99 billion, a price-to-earnings ratio of -51.23 and a beta of 1.67.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts' expectations of $314.23 million. During the same period in the prior year, the company posted ($0.44) EPS. The company's revenue was up 44.3% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -3.08 EPS for the current year.

Insider Buying and Selling

In related news, Director Ian T. Clark sold 14,180 shares of Guardant Health stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company's stock, valued at $472,787. This trade represents a 82.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Chris Freeman sold 63,605 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the transaction, the insider directly owned 65,374 shares of the company's stock, valued at approximately $11,086,122.92. The trade was a 49.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 178,940 shares of company stock valued at $30,070,911 over the last 90 days. 5.60% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company's products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient's response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.